PHARMACOKINETICS OF KETOTIFEN AFTER ORAL-ADMINISTRATION TO HEALTHY MALE-SUBJECTS

被引:23
作者
GRAHNEN, A [1 ]
LONNEBO, A [1 ]
BECK, O [1 ]
ECKERNAS, SA [1 ]
DAHLSTROM, B [1 ]
LINDSTROM, B [1 ]
机构
[1] KAROLINSKA INST,DEPT CLIN PHARMACOL,S-10401 STOCKHOLM 60,SWEDEN
关键词
KETOTIFEN; PHARMACOKINETICS; GC-MS;
D O I
10.1002/bdd.2510130404
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of 2 mg ketotifen from four different oral dosage forms were examined in two randomized, balanced cross-over studies. Forty healthy male subjects participated. Each of 20 subjects received two capsule formulations and each of the other 20 subjects received two syrup formulations. Ketotifen concentrations in plasma were determined by a modified GC-MS method. The limit of quantitation was 40 pg ml-1. Inter-day precision and accuracy calculated from quality control samples were 16.3 per cent (-1.9 per cent), 19.8 per cent (+4.5 per cent) and 23.6 per cent (+5.9 per cent) at plasma concentration levels of 86 (n = 18), 215 (n = 19) and 343 (n = 18) pg ml-1, respectively. Ketotifen was rapidly absorbed from all dosage forms reaching C(max) in the order of 400 pg ml-1 after the syrup formulations and 300 pg ml-1 after the capsule formulations within 2 to 4 h. The syrup formulations showed a significantly more rapid rate of absorption as assessed by T(max). No significant differences in extent of absorption between dosage forms were observed. The terminal elimination half-life of ketotifen varied between subjects from 7 to 27 hours with a mean of about 12 h. The minor pharmacokinetic difference between dosage forms observed in this study is unlikely to be of clinical significance.
引用
收藏
页码:255 / 262
页数:8
相关论文
共 10 条
[1]  
CRAPS L, 1980, ACTA THERAP, V6, P1
[2]   KETOTIFEN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN ASTHMA AND ALLERGIC DISORDERS [J].
GRANT, SM ;
GOA, KL ;
FITTON, A ;
SORKIN, EM .
DRUGS, 1990, 40 (03) :412-448
[3]   QUANTIFICATION OF KETOTIFEN AND ITS METABOLITES IN HUMAN-PLASMA BY GAS-CHROMATOGRAPHY MASS-SPECTROMETRY [J].
JULIENLAROSE, C ;
GUERRET, M ;
LAVENE, D ;
KIECHEL, JR .
BIOMEDICAL MASS SPECTROMETRY, 1983, 10 (03) :136-142
[4]  
Kennedy G.R, 1982, RES CLIN FORUMS, V4, P17
[5]  
MARTIN U, 1978, ARZNEIMITTELFORSCH, V28-1, P770
[6]  
MONIE RD, 1980, BR J DIS CHEST, V76, P383
[7]  
SCHMIDTREDEMANN B, 1986, INT J CLIN PHARM TH, V24, P496
[8]   A COMPARISON OF THE 2 ONE-SIDED TESTS PROCEDURE AND THE POWER APPROACH FOR ASSESSING THE EQUIVALENCE OF AVERAGE BIOAVAILABILITY [J].
SCHUIRMANN, DJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1987, 15 (06) :657-680
[9]  
TAUER AR, 1980, BR J DIS CHEST, V74, P398
[10]   A MULTICENTER TRIAL OF THE PROPHYLACTIC EFFECT OF KETOTIFEN, THEOPHYLLINE, AND PLACEBO IN ATOPIC ASTHMA [J].
TINKELMAN, DG ;
MOSS, BA ;
BUKANTZ, SC ;
SHEFFER, AL ;
DOBKEN, JH ;
CHODOSH, S ;
COHEN, BM ;
ROSENTHAL, RR ;
RAPPAPORT, I ;
BUCKLEY, CE ;
CHUSID, EL ;
DEUTSCH, AJ ;
SETTIPANE, GA ;
BURNS, RBP .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1985, 76 (03) :487-497